SGLT抑制剂治疗1型糖尿病时糖尿病酮症酸中毒风险管理的国际共识
SGLT抑制剂可有效降低1型糖尿病患者的糖化血红蛋白、血糖波动、血压和体重,且本身不引起低血糖。但近期研究显示其增加糖尿病酮症酸中毒(DKA)的绝对风险,部分病例血糖接近正常或仅轻度升高,导致识别和诊断困难并可能延误治疗。本共识报告回顾现有数据并提供建议,以提高SGLT抑制剂在1型糖尿病患者中的安全性。
要点
- SGLT抑制剂增加1型糖尿病患者DKA绝对风险,部分病例血糖接近正常。
- 血糖正常或轻度升高的DKA易被漏诊,需提高警惕。
- 需制定并推广策略以降低SGLT抑制剂相关DKA风险。
核心结论
- SGLT抑制剂在1型糖尿病中增加DKA绝对风险,部分病例血糖接近正常或轻度升高,需制定策略管理该风险。
研究设计与样本
- 国际共识报告,基于现有SGLT抑制剂在1型糖尿病中使用的数据回顾。
主要发现
- SGLT抑制剂有效降低1型糖尿病患者的A1C、血糖波动、血压和体重,且本身不引起低血糖。
- 近期研究显示1型糖尿病患者使用SGLT抑制剂后DKA绝对风险增加。
- 部分DKA病例表现为血糖接近正常或轻度高血糖,增加识别和诊断难度,可能延误治疗。
关键数值与推荐
- 共识提供建议以增强SGLT抑制剂在1型糖尿病患者中的安全性。
临床怎么用
- 临床应警惕SGLT抑制剂相关DKA,即使血糖接近正常或仅轻度升高也应考虑DKA可能。
- 需向医疗界推广降低DKA风险的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sodium-glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolute risk of diabetic ketoacidosis (DKA). Some cases presented with near-normal blood glucose levels or mild hyperglycemia, complicating the recognition/diagnosis of DKA and potentially delaying treatment. Several SGLT inhibitors are currently under review by the U.S. Food and Drug Administration and European regulatory agencies as adjuncts to insulin therapy in people with type 1 diabetes. Strategies must be developed and disseminated to the medical community to mitigate the associated DKA risk. This Consensus Report reviews current data regarding SGLT inhibitor use and provides recommendations to enhance the safety of SGLT inhibitors in people with type 1 diabetes.
引用
- Danne T, Garg S, Peters AL, et al. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019. PMID: 30728224. doi:10.2337/dc18-2316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。